Laura Carter

This profile gathers the share dealings of Laura Carter in Gossamer Bio, Inc., where the filings describe the role as senior executive. We count 10 filings; the first trade dates from 3 May 2021 and the latest from 16 March 2023.

In open-market terms, that means 1 purchase worth €50k on one side and 7 sales worth €266k on the other. Taken together, the sales exceed the purchases by €216k. Unlike grants, an open-market purchase is paid for by the insider, at the market price. Outside the open market, there are 2 share grants. Since January 2023: no purchases and 1 sale on the market.

On 20 March 2023 came the latest disclosure, an open-market sale for €6,255 in Gossamer Bio, Inc. The clock since the last published purchase (15 July 2022) now reads 1,556 days. The median gap between a trade and its publication by SEC (Form 4) is 1 day. Section 16 rules allow two business days to file each Form 4. Sales are harder to read than purchases, since they often meet personal needs such as tax or diversification. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.